Infl uenza viruses are responsible for the infl uenza outbreaks that lead to signifi cant burden and cause signifi cant morbidity and mortality worldwide. Based on the core proteins, infl uenza viruses are classifi ed into three types, A, B, and C, of which only A and B cause signifi cant human disease and so the vaccine is directed against these two subtypes only. The effectiveness of the vaccine depends on boosting the immune system against the serotypes included within it. As infl uenza viruses undergo periodic changes in their antigen, the vaccine is modifi ed annually to ensure susceptibility. In contrast to other countries, Saudi Arabia faces a unique and challenging situation due to Hajj and Umrah seasons, when millions of people gather at the holy places in Mecca and Madinah, during which infl uenza outbreaks are commonly found. Such challenges making the adoption of strict vaccination strategy in Saudi Arabia is of great importance. All efforts were made to develop this guideline in an easy-to-read form, making it very handy and easy to use by health care workers. The guideline was designed to provide recommendations for problems frequently encountered in real life, with special consideration for special situations such as Hajj and Umrah seasons and pregnancy.
I
nfl uenza virus causes signifi cant morbidity and mortality worldwide. [1] Persons infected by influenza virus may be asymptomatic or present with self-limited acute febrile respiratory symptoms. [2] However, those presenting with severe illness may have signifi cant morbidity and mortality. Such a presentation has been found to be associated with high-risk patients, e.g., elderly persons, young children, and patients of chronic medical conditions. [3] Though prophylaxis with antiviral agents may be used to prevent infl uenza transmission, vaccination is considered the best method for this purpose.
As part of the commitment of the Saudi Thoracic Society (STS) toward a long-term enhancement plan for promoting best practices in the fi eld of respiratory diseases, [4] [5] [6] [7] [8] a need for development of infl uenza vaccination guidelines was identifi ed. This is also justifi ed by the fact that Saudi Arabia hosts one of the major global mass gatherings by receiving millions of pilgrims from all over the world for the purpose of the Hajj and Umrah. Therefore, the Scientific Committee for Infl uenza and Pneumococcal Vaccination (SCIPV) guidelines was created by STS to establish local guidelines based on international recommendations on infl uenza vaccination, best practices, local literature, and the current settings in Saudi Arabia. The STS guidelines for infl uenza vaccination aims to standardize the approach among health care professionals (HCPs) in Saudi Arabia in an attempt to support the effort of different governmental agencies in this fi eld, with special attention for specifi c situations like the Hajj and Umrah. It also aims to disseminate knowledge about vaccination against common respiratory pathogens among HCPs through upto-date guidelines that are simple to understand and use. Of note, the recommendations related to infl uenza vaccination apply only to seasonal infl uenza and do not extend to other pandemics, like the avian fl u (H5N1).
Methods
The infl uenza vaccination guidelines are based on international guidelines and best practices. [2, 3, 9, 10] International guidelines on infl uenza vaccination were customized based on reviewing the available local literature, whenever available, and the current settings in Saudi Arabia, including statements released from governmental agencies. The SCIPV is a group of Saudi experts with well-respected academic backgrounds and experience in the fi eld of respiratory and infectious diseases. The consensus among the SCIPV was followed whenever there was a lack of appropriate evidence. [11] The following criteria were used to grade the evidence as:
• 
Epidemiology
Infl uenza is a common acute respiratory illness that occurs in outbreaks and epidemics worldwide, mainly during the winter season. Attack rates of seasonal infl uenza in the general population typically range from 7% to 18%, [3] [4] [5] whereas attack rates for pandemic infl uenza are estimated to range from 20% to 50%. [12] [13] [14] [15] [16] The peak of infl uenza attacks occurs between October and May in the Northern Hemisphere and between April and September in the Southern Hemisphere. The World Health Organization (WHO) estimated that infl uenza virus causes severe illness in 3-5 million people annually. [17] The case fatality of persons with two or more risk factors was estimated to be 377/100,000, compared with 9/100,000 for those without associated risk conditions. [18] [19] [20] Infl uenza vaccination was found to have a positive impact on health care, societal, and individual costs by reducing productivity losses and absenteeism associated with infl uenzarelated illnesses. [21] [22] [23] Though HCPs are among the high-risk group, there are reports showing their low compliance to annual influenza vaccination. [24] [25] [26] Saudi Arabia is not an exception as a survey conducted in the eastern province showed lower awareness of the benefi t of vaccination among HCPs. [27] In another survey conducted in six major hospitals in Saudi Arabia, the vaccination rate among HCPs was as low as 38%. Nonavailability of vaccine was considered by 43% of HCPs to be the highest barrier for not providing vaccine for patients. Furthermore, lack of awareness of influenza vaccination was reported by almost 75%. [28] In a campaign conducted in a tertiary care hospital in Saudi Arabia from 2003 to 2007, the coverage rate for HCPs was found to be 21-29%. [29] However, changing the methodology by engaging the Nursing Department as a partner in a vaccination campaign increased the coverage among nurses to 80%, physicians to 74%, and paramedical personnel to 67%.
A study during the H1N1 epidemic assessed knowledge and attitudes of the Saudi public reported that 38.3% of participants were not convinced about the truth of published reports about this illness. [30] Of those participants, 16.1% reported receiving information from health providers about infl uenza-related guidelines. Another study during the same epidemic confi rmed the need for prevention strategies, including immunization and improved personal hygiene in the Saudi population. [31] 
Virology
Infl uenza viruses have a single-stranded RNA genome and belong to the family Orthomyxoviridae. Infl uenza virus is classifi ed into three types based on their core proteins, type A, B, and C. Type A virus is further subdivided based on their outside envelope hemagglutinin activity or neuraminidase activity. [32, 33] Infl uenza B and C viruses mainly affect humans, whereas infl uenza A virus infects a range of mammalian and avian species and causes all infl uenza pandemics. While infl uenza C virus causes a mild form of the disease, types A and B can cause signifi cant human disease. [1] Infl uenza A virus undergoes high mutation rates. Major changes in the infl uenza A virus hemagglutinin and the neuraminidase are called antigenic shifts. This results in strains capable of causing epidemics or global pandemics. Minor changes so-called antigenic drifts occur almost annually and usually cause more localized outbreaks. [34] 
Clinical Manifestations
Infl uenza infection should be considered in immunocompetent or immunosuppressed person presents with fever and acute onset of respiratory symptoms and signs. The clinical illness of infl uenza can present as:
Uncomplicated infl uenza
In the majority of people, infl uenza is a self-limited infection that usually lasting 2-5 days following an incubation period of 1-4 days. However, the illness may occasionally last for 1 week or more especially in the elderlies, persons with chronic illnesses, and immunocompromised persons. Infl uenza infection presents with abrupt onset of fever, headache, myalgia, and malaise. It is also associated with respiratory tract manifestation that includes a sore throat, nonproductive cough, and nasal discharge. Fever usually ranges from 37.8°C to 40.0°C. Infl uenza may also present without fever especially in the older age group. Gastrointestinal manifestations can occur in 10-20% of infl uenza infections, especially in children. Some patients may have persistent symptoms of weakness or easy fatigability for several weeks, which is referred to as postinfl uenza asthenia. [2] Complicated infl uenza Infl uenza infection can progress to more serious complications, especially in high-risk groups [ Table 1 ], resulting in increased morbidity and mortality. [35] Pneumonia is the most common complication of infl uenza, which could be attributed to primary viral pneumonia that presents with severe symptoms, high fever, and dyspnea. It could progress quickly to respiratory failure in 2-5 days. [36, 37] Secondary, bacterial pneumonia is also an important cause of morbidity and mortality, especially among older persons. Patients typically relapse with higher fevers and productive cough after initial improvement in the symptoms of acute infl uenza. [38] The most common bacterial pathogens are Streptococcus pneumoniae followed by Staphylococcus aureus, and occasionally community-associated methicillin-resistant S. aureus. Haemophilus influenzae pneumonia may also complicate infl uenza. [39, 40] Mixed pneumonia can occur with features of both viral and bacterial pneumonia.
Other complications include myositis, rhabdomyolysis, myocarditis, pericarditis, and toxic shock syndrome. Central nervous system involvement includes encephalopathy, encephalitis, transverse myelitis, aseptic meningitis, and Guillain-Barre syndrome (GBS). [41] 
Transmission
Since the virus is present in the respiratory secretions of infected persons, large particle droplets (>5 μm) can easily be transmitted primarily through sneezing and coughing. [42, 43] As large particles travel for short distances of <1.5 m, transmission of infection requires close contact with an infected person. [44] The virus can also be transmitted by contact with surfaces that have been contaminated with respiratory droplets, including shaking hands. [45] Infectivity occurs with the shedding of the virus that starts 1-2 days prior to symptoms and until 5-7 days after the appearance of symptoms; 95% of the infectivity occurs in the fi rst 3 days. [46] The period of infectivity may last for 10 days or more in the elderlies, persons with chronic illnesses, and immunocompromised persons. [47] 
Infl uenza Vaccines
Infl uenza vaccination is the primary tool to prevent infl uenza infection rather than antiviral chemoprophylaxis. [48] The protection of infl uenza vaccine depends on inducing humoral immunity, namely neutralizing antibodies against viral capsular antigens, which boost the immune system against the serotypes included in the vaccine. As mentioned, infl uenza viruses undergo periodic changes in their antigenic envelope glycoproteins, the hemagglutinin (H) and the neuraminidase (N). This explains the spread of infection each year due to the susceptibility of the population to viruses with new antigens. [49] Hence, vaccines are produced annually to match circulating viruses. Three major subtypes of H (H1, H2, and H3) and two subtypes of N (N1 and N2) have been described.
Infl uenza B viruses have less tendency for antigenic changes. Although there are many subtypes of infl uenza A virus, 1-2 subtypes usually circulate among the human population at any given time. Therefore, most seasonal infl uenza vaccines include two subtypes of infl uenza A virus and one subtype of infl uenza B; hence, it is called a trivalent infl uenza vaccine (TIV). Recently, quadrivalent vaccines containing two infl uenza A antigens and two infl uenza B antigens were introduced. Occasionally, the monovalent vaccine is produced against a candidate pandemic strain, such as the H1N1 vaccine during the 2009/2010 epidemic.
Vaccine production takes about 6 months from the selection of strains to fi nal production and distribution. Two types of vaccines are produced annually; one for the Northern Hemisphere and the other for the Southern Hemisphere. This requires biannual productions of the vaccine to ensure its efficacy against related strains for both Hemispheres. Through the WHO global infl uenza surveillance and response system, the composition of the vaccine is adjusted based on the characteristics of circulating infl uenza viruses from the previous season.
[ 50, 51] In the Northern Hemisphere, vaccine strains are selected in February and made available in August of each year; in the Southern Hemisphere, vaccine strains are selected in September and made available in April of the following year. Infl uenza vaccines are manufactured in two forms: Inactivated infl uenza vaccines (IIVs) and live-attenuated virus vaccines (LAIVs). As the LAIV is not yet available in Saudi Arabia, infl uenza vaccination guidelines will focus on IIV (mainly TIV).
Inactivated infl uenza vaccines
The infl uenza vaccine currently available in Saudi Arabia for persons ≥6 months of age is TIV. [52] As the vaccine includes inactivated or killed virus, this vaccine is not considered infectious. It is administrated through intramuscular injection into the deltoid muscle of the arm [ Table 2 ]. Alternatively, it can be given subcutaneously in those persons with bleeding tendency, albeit with reduced effi cacy. [53] The protection of the vaccine depends on several factors, including the age and health status of the person being vaccinated and the match between the virus strains used in the vaccine and those circulating in the community. The overall effi cacy of inactivated vaccines in preventing laboratory-confirmed infl uenza is >60%. [54] [55] [56] [57] However, despite lower effi cacy in preventing infl uenza virus infection in elderly people, [58, 59] there is evidence that infl uenza vaccine lowers hospital admission rates for pneumonia and infl uenza, and is associated as well with reduction in mortality in elderly vaccines as compared to unvaccinated elderly persons. [60] Live-attenuated virus vaccine LAIV is administrated by the intra-nasal administration. Patients can shed vaccine virus strains from their upper respiratory tract for up to 7 days after receiving the LAIV and can test positive for infl uenza. [61, 62] Hence, the LAIV may cause a mild form of infl uenza illness. The LAIV is licensed for use among nonpregnant persons aged 2-49 years. [52] LAIV is not yet available in Saudi Arabia.
Indications
The SCIPV recommends the administration of the vaccine annually due to the modifi cation of its composition every [9, 124] year to match the annual circulating infl uenza virus strains. In Saudi Arabia, the vaccine is recommended during the infl uenza season that commences annually in September and ends in March of the following year. [63] The vaccination campaign should start soon after the availability of the vaccine. The SCIPV recommends the following for infl uenza vaccination administration [doses are available in Table 2 ]:
• All persons aged ≥6 months of age, including pregnant, and breastfeeding women (evidence A). [48, 52, 55, 64, 65] • For children aged 6 months through 8 years, vaccination is recommended based on previous vaccination history: • Previously vaccinated: Administer one dose only (evidence A). [9, 55, [66] [67] [68] • First-time vaccination: Administer two doses that are 4 weeks apart (evidence A). [55, 66, [69] [70] [71] • For children <6 months of age, vaccination is not recommended. However, it is rather recommended to ensure that people around these children are vaccinated: • When vaccine supply is limited, vaccination efforts should be prioritized by targeting certain categories: [72, 73] • Persons at higher risk for influenza-related complications [ Table 1 ] (evidence A). [65, 72, 74] • Healthcare professionals (evidence A). [75] [76] [77] [78] • Household contacts (children and adults) and caregivers of children aged <5 years with particular emphasis on vaccinating contacts of children aged <6 months (evidence A). [55, [78] [79] [80] • Household contacts (children and adults) and caregivers of adults aged ≥65 years and persons with medical conditions associated with higher risk for severe complications from infl uenza (evidence A). [74, [81] [82] [83] 
Contraindications
Infl uenza vaccination is recommended to be postponed if there is an acute illness, especially when associated with fever. However, whenever the acute illness is cured prior to discharge, administration of vaccination is recommended. The IIV is contraindicated in the following situations:
• Severe egg allergy. However, a person with mild allergy (e.g., hives) can receive IIV and must wait 30 min under observation in a clinical setting that can handle allergic reactions. [9] To deal with anaphylactic or hypersensitivity reactions, immediate treatment, including epinephrine 1:1000, should be easily accessible during the administration of the vaccine. [84] Formulations that are not produced in eggs are not yet available in Saudi Arabia. Whenever, there are signifi cant concerns, it is recommended to consult a physician specialized in allergic diseases.
• Previous history of severe allergy to any of the components of infl uenza vaccine.
• History of GBS within 6 weeks from receiving infl uenza vaccination. [52] • Children <6 months of age, as no vaccine is yet approved for this category.
If there is an epidemic of infl uenza in the community, antiviral prophylactic therapy might be administrated during the 2 weeks after receiving the vaccine to protect against the virus till the development of an adequate immune response. [85, 86] It can also be administered during the 6 weeks for children not previously vaccinated and who require two doses given at least 4 weeks apart.
Adverse Effects
The IIV is generally safe and well-tolerated in children and adults (evidence A). [87] [88] [89] However, self-limiting minor side effects have been frequently reported, especially for those who received the infl uenza vaccination for the fi rst time. [89] [90] [91] [92] The adverse effects include mild redness or swelling at the injection site, low-grade fever, minor body aches, and sore throat. The rate of occurrence of fever has been reported to be 12% in children aged 1-5 years, 5% in children aged 6-15 years and similar to placebo for adults. [52, 90] For those who are immunocompromised or have chronic diseases, available evidence does not show that IIV causes clinically important adverse effects. [93, 94] Mild and self-limited oculorespiratory syndrome has been reported to occur within 24 h after receiving IIV. [95, 96] However, a Canadian study found low recurrence rates of this complication after revaccination with IIV. [97] The presenting symptoms include red eyes, cough, wheezing, and chest tightness. However, it is still controversial whether this syndrome is a coincidental fi nding, or it is rather related to an immediate hypersensitivity reaction to any of the IIV components.
Serious adverse events have been rarely reported. The risk of anaphylaxis is very low (0.7 case/million doses) and considered a causal relation with influenza vaccine. Anaphylaxis is presumed to be allergic in nature and may present as hives, angioedema, wheeze and anaphylaxis. [98, 99] A slightly increased risk of GBS (1-2 cases/million) has also been reported in association with the infl uenza vaccine. [41] 
Infl uenza Vaccination for the Hajj and Umrah
The Hajj and Umrah are considered recurrent mass gatherings when millions of Muslims from all over the world come to the holy places in Mecca and Madinah in Saudi Arabia. Infections with infl uenza viruses are commonly found during these gatherings. [100] [101] [102] [103] In a study that compared the incidence of respiratory tract infections among pilgrims coming from Saudi Arabia and the United Kingdom (UK), the incidence of infl uenza was 10% in pilgrims from Saudi Arabia and 7% and 14% among vaccinated and nonvaccinated pilgrims from the UK, respectively. [101] As infl uenza vaccination is generally considered effective in reducing infl uenza-related infections, the SCIPV recommends that pilgrims get vaccinated at least 2 weeks before performing the Hajj or Umrah (evidence A). [101, 104] It is recommended to pay special attention to those suffering from chronic diseases (cardiac diseases, renal diseases, hepatic disease, respiratory diseases, nervous system disorders, and diabetes mellitus), immune defi cient patients (congenital and acquired), metabolic diseases, obese persons, pregnant women, and children aged <5 years. Similar recommendation has also been adopted by the Saudi Ministry of Health that pilgrims are to be vaccinated against seasonal influenza before their arrival into Saudi Arabia. [105] The Hajj seasons for the next few years will fall during the months of June to September. This raises special concern for the Hajj pilgrims arriving from tropical and subtropical areas, e.g., South and Southeastern Asia, where infl uenza positivity rates are higher during June to November compared with December to May. [106, 107] By collecting a weekly influenza surveillance data from 2006 to 2011 in these countries, Saha et al. reported the positivity rates during June to November to be 86% in Bangladesh, 80% in the Philippines, 70% in India, 43% in Indonesia, and 41% in Malaysia. [107] Therefore, the SCIPV recommends the administration of the Southern Hemisphere infl uenza vaccine prior to the Hajj and Umrah for pilgrims arriving from the Southern Hemisphere (evidence C). [106, 107] Furthermore, as the Northern Hemisphere infl uenza vaccine is not expected to be available prior to the Hajj in the next seasons for pilgrims from the Northern Hemisphere, the SCIPV also recommends the administration of the Southern Hemisphere infl uenza vaccine to those pilgrims prior to the Hajj session (evidence D). This should receive special attention as the composition of the current Southern Hemisphere vaccine is based on different characteristics of circulating infl uenza viruses utilized for the development of the Northern Hemisphere vaccine for the previous season. [108] 
Infl uenza Vaccination for Pregnant and Breastfeeding Women
When compared with nonpregnant women, pregnant women infected with infl uenza virus are prone to severe illnesses with higher morbidity and mortality. [109] [110] [111] They also have a greater risk for serious problems for their infants and during delivery. [112] [113] [114] Hence, seasonal infl uenza vaccine is commonly used during pregnancy. To assess the safety of infl uenza vaccine for pregnant women, the vaccine adverse event reporting system (VAERS) project collected reported adverse events in pregnant women receiving the vaccines from 1990 to 2009. [115] The VAERS project did not report unusual patterns of pregnancy complications or adverse fetal outcomes over these two decades. Along the same line, data from six health care organizations in the vaccine safety data link project showed no statistically signifi cant increase in the risk of pregnancy loss 4 weeks after IIV administration. [116] Furthermore, the passive transfer of antibodies from vaccinated women to their infants was found to reduce respiratory illness during the fi rst 6 months of life; hence IIV is not recommended for infants during that period. [117, 118] In a randomized controlled study, pregnant women who received seasonal infl uenza vaccine had a reduction in febrile respiratory illnesses by 36%. The vaccine effectiveness for infants was proven by a 63% reduction of laboratory-confi rmed infl uenza and 29% reduction in febrile respiratory illnesses. [118] Therefore, SCIPV recommends IIV infl uenza vaccination for pregnant women at any stage of pregnancy (evidence A). [118] [119] [120] [121] [122] [123] This recommendation is also extended to postpartum and breastfeeding women.
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